It is not the same with or without GalChimia
GALICIA EXPORTA EMPRESAS: GalChimia has been awarded the subsidy “GALICIA EXPORTA EMPRESAS” to support the implementation of its internationalization plan. This will allow to increase the number of international promotional activities such as:
- Attendance at international fairs and congresses of pharmaceutical and agrochemical sectors.
- SEO through a Community Manager.
- Graphical design for a new marketing campaign and production of promotional material.
CONVOCATORIA 2016 DAS AXUDAS DO IGAPE PARA A EXECUCIÓN DE ACCIÓNS DE PROMOCIÓN EXTERIOR DAS EMPRESAS GALEGAS (GALICIA EXPORTA EMPRESAS), COFINANCIADAS POLO FONDO EUROPEO DE DESENVOLVEMENTO REXIONAL NO MARCO DO PROGRAMA OPERATIVO FEDER GALICIA 2014-2020.
- Expediente: IG230.2016.1.88
- Importe do proxecto: 49.307,80 €
- Importe da subvención: 36.980,85 €
RESULTS FIRST PERIOD:
Thanks to this project, in period 1, GalChimia could participate in the following events:
- Frontier in Med Chem (13-16 march in Bonn – GE)
- 252nd ACS National Meeting & Exposition (21-25 August in Philadelphia – USA)
- XXIV EFMC International Symposium on Medicinal Chemistry (28 Ag-01 Sep in Manchester – UK)
- CIR Conference and Exhibition (4-6 Oct in Nice – FR)
Evaluation of flow chemistry technique for pyrazole synthesis.
Research and synthesis of new metabolites for agrochemical product such as the deltamethrin.
BIOGREEN: GalChimia participates in BIOGREEN, an R&D project aimed to develop a concept of green biorefinery that uses biomass as raw material, specifically high yield crops not intended as food sources, to obtain high added value products as bioplastics, celullose acetate films and fertilizers. The project will help to drive the bioeconomy concept and to integrate the circular economy model into fields traditionally agricultural, improving its competitiveness.
The BIOGREEN project will be developed in collaboration with the companies Norvento, Agroamb Prodalt, Biot and Idener, and with the technological centers AINIA and CETIM, and is subsided by the Centro para el Desarrollo Tecnológico Industrial (CDTI), the European Regional Development Fund (ERDF) and supported by the Spanish Ministry of Economy and Competitiviness. BIOGREEN has been one of the projects selectdd by CDTI in the last edition of the INNTERCONECTA program.
NEOGALFARM: Project in collaboration with Amslab, Nanogap, Oncostellae and several research groups from the University of Santiago de Compostela (USC), The Health Research Institute of Santiago de Compostela (IDIS) and LEITAT, with the objective: Found new treatments for cancer with the Development of therapies aimed at different therapeutic targets and combined treatments. This Project is granted by the Agencia Gallega de Innovación (GAIN) through the Conecta Pyme Program, co-financied by European Regional Development Fund (ERDF) and supported by the Consellería de Economía, Emprego e Industria (Xunta de Galicia). The total budget was fixed at 1,076,339.63 euros.
MYTITOX: Together with the companies Pescados Marcelino, PAYPAY, Marisco Veiro, Depuradora de Molusco La Sirena and the academic centers ANFACO-CECOPESCA and the International Iberian Nanotechnology Laboratories, GalChimia is taking part to the MytiTox Project. The objective of the project is based on the elaboration of industrial protocols, using microencapsulated active product, for the detoxification of mussels. MytiTox has been financed by the Spanish government and the European Union through the program FEDER INNTERCONECTA 2015. The budget was fixed at 1.461.272,00 euros.
Feder Funds – Operational Program to Drive Smart Growth Strategy 2014 – 2020
NANOFACTURING: GalChimia, Applus+ Laboratories, Midatech, Prochimia, Centre for Process Innovation and three Academic groups participate in the research Project entitled “NanoFacturing – The Development of Medium- and Large-Scale Sustainable Manufacturing Process Platforms for Clinically Compliant Solid Core Nanopharmaceuticals”. The main objective of the project is to develop a new manufacturing platform process for solid core nanopharmaceutical products, capable of being scaled up to supply Phase III trials and beyond, which is cost-effective, safe, efficient, robust and regulatory compliant. GalChimia is specifically involved in the synthesis of the ligands used to bind the nanoparticle to another chemical or biological molecules. The project has been financed by the European Union through the Horizon 2020 programme.
HOTDROPS: GalChimia, Novozyme, Biochemize, Drop-Tech and four Academic groups participate in the research project HotDrops, whose goal is to develop a new ultrahigh-throughput platform to search for new biocatalysts, with which large enzyme-variant libraries that were previously challenging to handle can now be screened. Single bacterial cells or in vitro transcription/translation systems can be compartmentalised into droplets, each expressing a different gene library variant. This project combined three sciences: enzymology, microfluid technology and organic chemistry. The project has been financed by the European Union through the Seventh Framework Programme (FP7).
ONCOGALFARMA: GalChimia, Oncostellae and AMSLab are participating in the research project Oncogalfarma, whose goal is to develop new complementary therapies for the treatment of oncological diseases. The research is centred in the fields of inhibitors of protein-protein interactions (PPI) and nuclear receptors. The project has been financed by the government of Galicia and co-financed by the European Regional Development Fund through the subprogramme CONECTA PEME. The total funding granted was €189,943.59. More information available.
LENBDA: The project “Light emitting nanomolecules for biomedical diagnostics applications (LENBDA)” is intended to study the industrial use of a biomolecules detection system based on highly specific luminescent nanoemitters. The system offers a complete solution for detecting biomolecules in a specific, interference-free way. To accomplish this goal, a fully functional prototype of the diagnostic kit will be developed to be used in pathology labs , so no additional equipment will be needed. At the final stage, the project will be validated against tumour cell lines available in tissue banks. The project has been financed by the government of Galicia and the European Regional Development Fund through the subprogramme CONECTA PEME. The total funding granted was €161,622.94.
HUMANFARMA: GalChimia is a member of the consortium Humanfarma, whose goal is to develop new active compounds for drug discovery through translational research directly in patient samples. The project, which has a budget of €4.1 M and has been partially financed by the Ministry of Economy and Competitiveness under the INNPACTO subprogramme, also involves the participation of the University of Santiago de Compostela (USC), the Barcelona Science Park (PCB) and three biotech companies: Oryzon Genomics, Vivia Allosterics and Vivia Biotech, coordinator of the project.
CORMPOI: The biotechnology company Alfama, with sites in Lisbon and Boston, is the world leader in CO-releasing molecule (CORMs), compounds with powerful vasodilatation activity. GalChimia has partnered with Alfama to develop CORMs for the Postoperative Ileus (POI), a condition usually found in patients who have undergone surgery; GalChimia’s synthetic expertise complements the Alfama’s deep biological knowledge of CORMs.
INTEREMPRESAS CDTI: These project was developed in close collaboration with Esteve Quimica and it was funded by the national grant, CDTI. The main objective is to evaluate and develop innovative routes of synthesis for generic products or APIs closed to patent expiry. To do so, it is important to identify new routes with a clear competitive advantage in terms of cost or yield, and/or using intermediaries or catalyser cheaper and/or using cleanest and most efficient technologies.